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Background: Curcumin is a natural polyphenol with anti-inﬂammatory, chemopreventive
and anticancer activity. However, its high hydrophobicity and poor bioavailability limit its
medical application. The development of nanocarriers for curcumin delivery is an attractive
approach to overcome its low bioavailability and fast metabolism in the liver. We synthesized
a blood compatible alginate-curcumin conjugate, AA-Cur, which formed colloidally stable
micelles of approximately 200 nm and, as previously shown, exerted strong cytotoxicity
against mouse cancer cell lines. Here we analyze in vivo toxicity and antitumor activity of
AA-Cur in two different mouse tumor models.
Method: Potential toxicity of intravenously injected AA-Cur was evaluated by: i) analyses
of blood parameters (morphology and biochemistry), ii) histology, iii) DNA integrity (comet
assay), and iv) cytokine proﬁling (ﬂow cytometry). Antitumor activity of AA-Cur was
evaluated by measuring the growth of subcutaneously inoculated colon MC38-CEA- or
orthotopically injected breast 4T1 tumor cells in control mice vs mice treated with AA-Cur.
Results: Injections of four doses of AA-Cur did not reveal any toxicity of the conjugate,
thus indicating the safety of its use. AA-Cur elicited moderate anti-tumor activity toward
colon MC38-CEA or breast 4T1 carcinomas.
Conclusion: The tested conjugate of alginate and curcumin, AA-Cur, is non-toxic and safe,
but exhibits limited anticancer activity.
Keywords: curcumin, alginate conjugates, in vivo toxicity, antitumor activity
Introduction
Curcumin (diferuloylmethane) is a natural polyphenol from Curcuma longa and has
been used in Asian cuisine for more than 5000 years. It has also been employed for
centuries in the traditional medicine of the Far East as a painkiller and for the
treatment of infections, as well as skin and digestive diseases. The last 50 years of
research, both in vitro and in animal models, have conﬁrmed that curcumin has strong
anti-inﬂammatory, antioxidant, antimutagenic, and bactericidal properties, hence it is
regarded as a good candidate for the treatment of diabetes, psoriasis, rheumatoid
arthritis, chronic enteritis, cardiovascular diseases, Alzheimer’s disease, and cancer.1
The difﬁculty of this approach, recognized already by Wahlstrom in 1978, lies in the
very low bioavailability of curcumin caused by its high hydrophobicity. After oral
administration of a very high dose of curcumin to animals (1 g per 1 kg of body
mass), over 70% of this compound was excreted in the feces. The rest, absorbed from
the gut to the circulation, underwent rapid transformation in the liver into inactive
metabolites.2 These observations have been conﬁrmed by numerous clinical studies
which showed very low plasma levels of curcumin after its oral administration.
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Recently, highly water-soluble complexes of curcumin
and Eudragit polymers have been generated for the treatment
of inﬂammatory bowel disease after oral administration.3,4
The problem of poor absorption and immediate curcu-
min degradation in the liver could be, at least partially
resolved by its intravenous application.
However, as the compound dissolves only in organic
solvents such as dimethyl sulfoxide (DMSO), ethanol or
acetone, a suitable formulation compatible with needs to
be developed to enable this route of administration. Two
approaches are currently being tested: i) developing a
nanomaterial-based curcumin delivery system and ii)
introducing chemical modiﬁcations into a curcumin mole-
cule to generate its derivative with preserved biological
activity but signiﬁcantly enhanced bioavailability and
resistance against liver-mediated degradation. The ideal
delivery system should allow an effective and selective
transport of curcumin to the diseased tissue, preferably
with the omission of the liver to avoid or at least limit
curcumin conversion to inactive derivatives. Various nano-
carriers have already been proposed for curcumin, includ-
ing liposomes, poly(lactic-co-glycolic acid) (PLGA)
nanocapsules, polysaccharide micro- and nanoparticles,
and gold- and silver nanoparticles.5–9 The second
approach, the chemical modiﬁcation of curcumin, often
involves its conjugation with hydrophilic polymers such
as polyethylene glycol, PLGA, dextran, carboxymethyl
chitosan, hyaluronic acid, or alginate.10–17
We have previously described the synthesis of alginate-
curcumin conjugate (AA-Cur) forming colloidally stable
micelles of approximately 200 nm in diameter. We con-
ﬁrmed that AA-Cur was taken up by cancer cells, was not
toxic for cells isolated from human blood or for mouse
endothelial cells, and exerted strong cytotoxic activity
against different mouse cancer cell lines.16 The promising
results of those experiments encouraged us to continue our
studies in order to test the in vivo toxicity and anticancer
activity of the intravenously administered AA-Cur
conjugate.
Materials and methods
Preparation of bioconjugate of alginate
and curcumin (AA-Cur)
The bioconjugate of alginate and curcumin (AA-Cur) was
synthesized and characterized according to the procedures
described by us previously.16 Brieﬂy, 75 mg of N,Nʹ-dicy-
clohexylcarbodiimide 8 and 30 mg of 4-(dimethyl)
aminopyridine was added to 600 mg of alginic acid
sodium salt from brown algae (AA) dissolved in 150 mL
of DMSO. Next, 25 mL of 0.152 mM curcumin solution in
DMSO was added and the mixture was stirred for 6 hrs at
63°C in the atmosphere of argon. Directly after synthesis,
the reaction mixture was cooled down and dialyzed in a
dialysis tubing (molecular weight cut-off 12 kDa) in room
temperature (RT) for the ﬁrst 24 hrs against DMSO and for
the following 7 days against water (pH = 7). The resulting
solution was centrifuged (20 mins, 10,000xg at 4°C) to
remove solid traces of unbound curcumin and lyophilized.
The successful synthesis was conﬁrmed by 1H Nuclear
Magnetic Resonance (1H NMR), Fourier Transform
Infrared (FTIR) and UV-Vis absorption spectroscopies.
Apparatus
Dynamic light scattering (DLS) measurements were per-
formed using NANOSIZER-ZS (Malvern Instruments,
Malvern, UK). The sample was illuminated with a 633-
nm laser, and the intensity of light scattered at 173º was
measured by an avalanche photodiode. The measurements
were performed at 25°C.
Transmission electron microscopy (TEM) images were
obtained using Tecnai TF 20 X-TWIN (FEI) microscope
(FEI, Hillsboro, OR, USA). Cross-linked micelles were
deposited onto an ultrathin carbon ﬁlm on a holey carbon.
The mean size and the size distribution were obtained by
ﬁtting circles around the lattice fringes of the micelles and
measuring their diameters.
Cell lines
MC38-CEA is a murine colon adenocarcinoma with stable
expression of human carcinoembryonic antigen (CEA).
MC38 was a gift from Professor Schabel FM and was stably
transfected with DNA coding for CEA by Dr. Michał Bereta
(Jagiellonian University, Kraków).18 The Animal Welfare
Committee at the Faculty of Biochemistry, Biophysics and
Biotechnology, Jagiellonian University has approved the
usage of this cell line.
4T1 cell line (murine mammary carcinoma that stably
expresses a ﬁreﬂy luciferase) was purchased from Dr Gary
Sahagian’s lab (Tufts University, Boston).
Animals
Six-week-old C57BL/6 female mice were obtained from
the Animal Facility of the Faculty of Biochemistry,
Biophysics and Biotechnology, Jagiellonian University,
Kraków, Poland. Six-week-old BALB/c female mice
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were purchased from the Centre of Experimental Medicine
of the Medical University of Białystok, Poland. Animals
were housed under controlled conditions and provided
with food and water ad libitum. All animal procedures
were performed pursuant to Polish law, and speciﬁcally
to the Act on the Protection of Animals used for Scientiﬁc
or Educational Purposes (D20150266L), which imple-
ments the Directive of the European Parliament and the
Council (2010/63/EU). All experimental procedures were
in agreement with the guidelines of the Institutional
Animal Care and Use Committee (IACUC) and were
approved by the 2nd Local IACUC in Kraków.
Analysis of in vivo toxicity of AA-Cur
Intravenous administration of AA-Cur conjugate
C57BL/6micewere weighted and randomly divided into two
experimental groups (n=9). On day 0 of the experiment, the
animals were injected in the tail vein with 200 µL of 0.9%
NaCl (group 1) or 200 µL of 0.9% NaCl containing AA-Cur
in a dose of 70 mg/kg of body mass (bm) (group 2).
Collection of blood, organs, and bone marrow-
derived cells for toxicity analysis
Three days after ﬁrst injection and 1 day before euthanasia
blood was taken from the facial vein for hematological
analysis. On 30th day of the experiment, the animals were
euthanized using an intraperitoneal injection of ketamine
(50 mg/kg bm) and xylazine (5 mg/kg bm). Blood was
drawn postmortem by cardiac puncture and was allowed to
clot and centrifuged (800xg, 10 mins, RT). Serum, isolated
by centrifugation (800×g, 10 mins, RT) was used for
biochemical analysis and cytokine proﬁling. Major organs:
the liver, spleen, and kidneys were isolated, weighted and
transferred to 4% formaldehyde for histological analysis.
Additionally, bone marrow-derived cells were isolated by
ﬂushing femurs with PBS in order to analyze DNA
damage (comet assay). The organ-to-body mass indexes
were calculated according to the following equation:
organ/body mass index = organ mass/body mass.
Hematological and serum biochemical analyses
The blood collected from facial vein was analyzed for
hematological parameters: counts of white blood cells,
red blood cells, platelets, granulocytes, lymphocytes,
monocytes, hematocrit, mean corpuscular volume, hemo-
globin concentration , and red cell distribution width using
a fully automated veterinary analyzer ABC Vet
(HORIBA®, UK). The samples of sera separated from
blood (collected by cardiac puncture) were analyzed
using Spotchem EZ Chemistry Analyzer (Woodley;
Lancashire, UK) and multiparameter strips: Spotchem II
Panel V, according to the manufacturer’s instructions. The
following biochemical parameters were measured: activ-
ities of ALP and alanine transaminase (ALT), concentra-
tions of total protein (T-Pro), creatinine (Cre) and blood
urea nitrogen (BUN).
Quantiﬁcation of cytokines
Serum concentrations of cytokines: IL-1α, IL-1β, IL-6, IL-10,
IL-12p70, IL-17α, IL-23, IL-27, MCP-1, interferon-β (IFN-β),
IFN-γ, tumor necrosis factor-α (TNF-α), and GM-CSF were
measured using LEGENDplex Mouse Inﬂammation Panel
(13-plex) immunoassay (Biolegend; San Diego, CA, USA)
and BD LSRFortessa ﬂow cytometer and analyzed using
LEGENDplex software (Biolegend).
Histological analysis
Histological evaluation of 3 µm-thin slices of formalin-ﬁxed,
parafﬁn-embedded organs (liver, kidney, spleen) was per-
formed after staining with hematoxylin/eosin (H&E).
Comet assay
DNA damage in bone marrow-derived cells (1×105 cells/
100 µL of PBS) was assessed by comet assay, according to
the previously described procedure.19 Fifty cells were ran-
domly selected from two slides per sample and percentage
of DNA in the comet tail (% DNA damage) was deter-
mined for each cell using epiﬂuorescence microscope
(Olympus IX-50, Olympus Corporation, Tokyo, Japan)
with CCD camera and COMET ASSAY 2.9 software
(Comet Plus, Theta System GmbH, Germany).
Analysis of antitumor activity of AA-Cur
in two tumor models: MC38-CEA colon
carcinoma and 4T1 breast carcinoma
Mice were weighted and randomly divided into two experi-
mental groups (control and AA-Cur-treated). Tumor cells
MC38-CEA or 4T1 were cultured in 10-cm dishes in
DMEM medium (Lonza; Basel, Switzerland) supplemented
with 10% FBS (Gibco, Waltham, MA, USA). The cells were
trypsinized (0.05% trypsin, 0.53 mM EDTA, Lonza) and
centrifuged (450×g for 5 mins at RT). After discarding the
supernatant, the cells were washed with 10 mL PBS (Lonza),
centrifuged and resuspended in PBS to a ﬁnal density of
5×105 cells/0.1 mL. MC38-CEA cells (5×105) were injected
subcutaneously (s.c.) into the left ﬂank of C57BL/6 mice
(n=9) and 4T1 cells (5×105) orthotopically into the fourth
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mammary fat pad of BALB/c mice (n=12). Seven days later,
mice were injected intravenously with 0.9%NaCl or AA-Cur
(70 mg/kg bm). The animals continued to receive four doses
of AA-Cur (in 2- or 3 days intervals). The values of body
mass and tumor size were recorded in 3-day intervals. Mice
were euthanized 2 or 3 days after the last dose of AA-Cur (on
15th or 21st day of the experiment for C57BL/6 andBALB/c,
respectively). Blood and tumors were isolated for further
analyses.
Statistical analysis
Statistical signiﬁcance was analyzed by the multiple t-test with
the use of GraphPad Prism 6 (GraphPad Software, Inc., La
Jolla, CA, USA), with P<0.05 being considered signiﬁcant.
Results
Synthesis of AA-Cur
The successful synthesis of AA-Cur conjugate was con-
ﬁrmed by FTIR, 1H NMR and UV-Vis absorption spectro-
scopies. The detailed synthesis procedure and the obtained
AA-Cur spectra were presented and discussed in the
Supplementary Materials section of our previous paper.16
Based on the spectrophotometric analysis the curcumin
content in 1 g of AA-Cur conjugate was estimated as 45
mg (4.5 wt%). AA-Cur exhibits high solubility in water (7
mg/mL), as can be observed in Figure 1. Due to the
amphiphilic character of the conjugate, it aggregates in
aqueous solutions forming micelles. The critical micelle
concentration (cmc) for AA-Cur was established based on
conductometric titration to be 0.654 mg/mL. DLS mea-
surements presented in our previous paper allowed to
estimate the average diameter of the micelles formed as
205 nm.16 The average zeta potential value measured for
the micelles was −53 mV, which is a value high enough to
ensure good colloidal stability of the AA-Cur micelles.
The model studies have shown that at 37 ºC curcumin
is released from the conjugate dissolved in phosphate
buffer (pH = 7.4) to the oleic acid phase gradually, without
burst effect, over a period of 5 hrs.16 When pH of the
aqueous phase was decreased to mimic the environment of
cancer tissue the release was much faster – almost all
curcumin was released within 1 hr. Further studies of the
AA-Cur micelles showed that, based on TEM measure-
ments, the diameter of the cross-linked micelle in the dry
state is in the range of 160 nm (Figure 2) and is smaller
than that obtained from DLS. This is expected, as the
hydrodynamic diameter of the micelle includes the solva-
tion shell, which is not present in the TEM images of the
dried material. Additional DLS studies performed at var-
ious pH values revealed that with increasing pH the AA-
Cur micelles tend to swell, but in the physiologically
relevant pH range (6.5–7.4) the observed effect is rela-
tively small (<50%). The obtained results are presented in
Table 1.
Figure 1 A photograph of the glass bottles containing the same amount of
curcumin in the form of (from left to right): AA-Cur conjugate in PBS, free curcumin
in PBS (undissolved on the bottom of the bottle) and free curcumin in DMSO.
Abbreviations: AA-Cur, alginate-curcumin conjugate; DMSO, dimethyl sulfoxide.
Figure 2 TEM image of the AA-Cur micelle cross-linked with calcium ions.
Abbreviations: AA-Cur, alginate-curcumin conjugate; TEM, transmission electron
microscopy.
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Analysis of in vivo biocompatibility of
AA-Cur
The analysis of AA-Cur conjugate biocompatibility was
performed after repeated intravenous injections of C57BL/
6 mice with micellar solution of AA-Cur (70 mg/kg bm,
once a week for 4 weeks). The animals were sacriﬁced on
the 30th day of the experiment. This experimental
approach allowed to analyze the potential short- and
long-term toxicity of the tested micelles.
AA-Cur does not cause any alterations in
hematological parameters
The animals injected with 4 doses of AA-Cur within a
month did not present any weight alteration or changes in
the size of main internal organs (data not shown) indicat-
ing the lack of acute toxicity of the tested micelles.
Analysis of the main hematological parameters performed
3 days after ﬁrst injection of AA-Cur and 1 day before
Table 1 Hydrodynamic diameter (dz) for AA-Cur conjugate
solutions (0.6 mg/mL) at different pH. The presented results
are the average of three measurements
pH dz [nm]
6.0 103.7
6.5 164.2
7.4 205.4
8.0 205.4
Figure 3 Blood hematology analysis of C57BL/6 mice treated with AA-Cur.
Notes: Animals were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm). Administrations were repeated once a week for 4 weeks. Animals were euthanized on 30th day
of the experiment. Blood was drawn from the facial vein 1 day before euthanasia. Each point on the graph represents individual mouse. The line for each group represents
the mean ± SD (n=9).
Abbreviations: AA-Cur, alginate-curcumin conjugate; HGB, hemoglobin concentration; HCT, hematocrit; GRA, granulocytes; LYM, lymphocytes; MON, monocytes; MCV,
mean corpuscular volume; WBC, white blood cells.
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euthanasia (after injections of four doses of the conjugate)
also revealed no toxic effects of AA-Cur toward blood
cells (Figure 3). Additionally, we did not observe any
increase in DNA damage in bone marrow-derived cells
of AA-Cur-treated animals, quite contrary, the percentage
of damaged DNA was slightly higher in the cells of con-
trol- vs AA-Cur-injected mice and may indicate protective
activity of AA-Cur (Figure 4).
AA-Cur does not cause liver, kidney, and
spleen injury
The analysis of organ to body mass indexes did not reveal any
alteration in size of major organs such as the liver, kidney, and
spleen (data not shown). The potential AA-Cur-induced injury
of the liver or kidneys was also analyzed by biochemical
analysis of main markers of hepatotoxicity or nephrotoxicity
in sera isolated from blood taken postmortem by cardiac punc-
ture (on the 30th day of the experiment). Measurements of
serum activities of the main liver enzymes (ALP, ALT) and
concentrations of non-enzymatic markers of liver injury (glu-
cose and T-Pro) or renal failure (Cre and BUN) indicated no
hepatotoxicity and nephrotoxicity of testedmicelles (Figure 5).
These results were conﬁrmed by histological assessment,
which did not demonstrate any liver or kidney abnormalities
(Figure 6).
AA-Cur leads to decrease in basal
concentration of several cytokines in
healthy animals
We performed the analysis of cytokine levels in sera
obtained from C57BL/6 mice exposed to four doses of
AA-Cur. We observed decreased concentration of IL-23
and IL-1α in sera of mice injected with AA-Cur micelles
in comparison to those of control animals (Figure 7). The
concentrations of IFN-γ, IL-12p70, IL-1β were also lower
in sera of AA-Cur-treated animals, however, the observed
differences did not reach statistical signiﬁcance. The con-
centrations of TNF-α, GM-CSF, IL-27, IL17α, IFN-β, IL-
6, IL-10, and MCP-1 were similar to those obtained in
control animals. Histological analysis also excluded altera-
tion of spleen morphology (Figure 6).
Antitumor activity of AA-Cur
To evaluate the potential anti-tumor activity of AA-Cur,
two different mouse tumor models were used. In the ﬁrst
one, C57BL/6 mice were inoculated subcutaneously with
colon carcinoma MC38-CEA cells. In the second one,
breast cancer 4T1 cells were injected orthotopically, i.e.,
into the mammary fat pad of BALB/c mice. In both
models, 7 days after injection of tumor cells, animals
were given the ﬁrst of four iv doses of AA-Cur. As pre-
sented in Figure 8, AA-Cur had moderate effect on the size
of MC38-CEA and 4T1 tumors. The mean tumor weight
of the mice from control groups was 0.79 g and 0.16 g (for
MC38-CEA or 4T1 tumors, respectively) versus 0.45 g
and 0.11 g for groups treated with AA-Cur (for MC38-
CEA or 4T1 tumors, respectively). Thus, although the
changes in the size of tumors did not reach statistical
signiﬁcance, in both models the average tumor masses in
mice treated with AA-Cur were more than 30% lower than
those in control mice.
Additionally, we evaluated serum cytokine proﬁles in
tumor-bearing mice untreated and treated with AA-Cur.
Similarly to the results of cytokine measurements in
healthy animals, we observed slightly decreased concen-
trations of IL-23 and IL-1α in the serum of mice bearing
MC38-CEA tumors injected with AA-Cur than in those
injected with vehicle, however, the changes did not reach
statistical signiﬁcance (Figure 9). Animals with 4T1
tumors exposed to AA-Cur had lower levels of several
cytokines including IL-6, IL-1β, IL-27, IL-17α, IFN-β,
however, statistically signiﬁcant changes were observed
only for IFN-γ and IL-10 (Figure 10).
Figure 4 Comet assay analysis of DNA damage in bone marrow-derived cells
isolated from C57BL/6 mice treated with AA-Cur.
Notes: Animals were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm).
Administrations were repeated once a week for 4 weeks. Animals were euthanized on
30th day of the experiment and bone marrow-derived cells were isolated. Percentage of
DNA in the comet tail (% DNA damage) was analyzed for two slides per sample and 50
cells from each slidewere randomly selected for analysis. Each point represents individual
mouse. The line for each group represents the mean ± SD (n=6). *P<0.05.
Abbreviation: AA-Cur, alginate-curcumin conjugate.
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Figure 5 Biochemical serum analyses of C57BL/6 mice treated with AA-Cur.
Notes: Animals were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm). Administrations were repeated once a week for 4 weeks. Animals were euthanized on the 30th
day of the experiment. Blood was taken postmortem by cardiac puncture. Each point represents individual mouse. The line for each group represents the mean ± SD (n=8).
Abbreviations: AA-Cur, alginate-curcumin conjugate; BUN, blood urea nitrogen.
Figure 6 Histological analysis of the liver, kidney and spleen isolated from animals after repeated administration of AA-Cur.
Notes: Animals were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm). Administrations were repeated once a week for 4 weeks. Animals were euthanized on 30th day
of the experiment. Representative pictures of tissue sections from three mice are presented.
Abbreviation: AA-Cur, alginate-curcumin conjugate.
Dovepress Karabasz et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
7255
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Discussion
Numerous studies have indicated that various delivery
systems used for encapsulation of curcumin including
liposomes, polymeric nanoparticles, or polymeric micelles
might be a promising carriers for poorly aqueous soluble
curcumin.20 Another approach to overcoming the problem
of low bioavailability of curcumin is its conjugation with
hydrophilic polymers. Recently, many different curcumin
bioconjugates have been synthesized, however, most of
them have only been tested in vitro.12,21–25 Therefore, little
is known not only about the systemic toxicity of curcumin-
polymer conjugates but also about their biological activity
in vivo. Moreover, the toxicity of curcumin either free or
encapsulated in nanoparticles has been studied primarily
after oral administration, hence little is known about its
possible toxic effects after intravenous injection.26–28
Figure 7 Quantiﬁcation of cytokine concentrations in sera of healthy C57BL/6 mice treated with AA-Cur.
Notes: Animals were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm). Administrations were repeated once aweek for 4 weeks. Animals were euthanized on 30th day of the
experiment. Sera were obtained from blood taken by cardiac puncture. Each point represents individual mouse. The line for each group represents the mean ± SD (n=5). *P<0.05.
Abbreviations: AA-Cur, alginate-curcumin conjugate; IFN, interferon; TNF, tumor necrosis factor.
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The aim of this study was to investigate the toxicity and
anti-tumor activity of intravenously administered micelles of
AA-Cur, the alginate-curcumin conjugate. We evaluated the
toxicity of AA-Cur after administration of four doses of the
conjugate. In this study, we did not use free curcumin as a
reference because our previous in vitro analyses demon-
strated that curcumin dissolved in DMSO (at the ﬁnal
concentration of 5.95 μg/mL, comparable to this in algi-
nate-based micelles) exerted very weak cytotoxicity against
the tested tumor cells.16 Alginates are biocompatible, non-
immunogenic and nontoxic polysaccharides approved by US
Food and Drug Administration (FDA) for the use in food and
pharmaceutical industry.29,30 Therefore, in the experiments
concerning toxicity and activity of AA-Cur we used saline
(AA-Cur solvent) as a control. The dose of AA-Cur (70 mg/
kg of bodymass) used in the experiments corresponds to 3.15
mg of intravenously administered pure curcumin per kg bm.
The results proved the lack of in vivo toxicity of repeatedly
injected AA-Cur in healthy animals. First of all, we did not
observe changes in the general hematological parameters.
This is in line with the already published results of our in
vitro studies, which showed that AA-Cur is not toxic to cells
isolated from human blood.16 In contrast, Storka et al demon-
strated that intravenous administration of liposomes loaded
with curcumin may result in transient changes in red blood
cell morphology and increased mean cellular volume of red
cells in healthy human subjects. This probably results from
interaction between erythrocytes and DPMC (1,2-dimyris-
toyl-sn-glycero-3-phosphocholine) used for the synthesis of
liposomes.31 The serum biochemical analyses demonstrated
that AA-Cur-treated animals had no liver or kidney injury.
These results are consistent with previously published data,
which ruled out the idea of possible hepatotoxicity and
nephrotoxicity of curcumin.32–35
Curcumin exerts cancer chemopreventive effects via,
among others, protection of cells from DNA damage,
however, high doses of curcumin may induce DNA
damage by increasing level of ROS (reactive oxygen spe-
cies) or by inﬂuencing activity of various proteins includ-
ing DNA topoisomerases or tumor suppressor p53.26,36–38
Analysis of DNA damage in bone marrow-derived cells
did not show any negative effects of AA-Cur conjugates.
Quite the contrary, we observed that the basic level of
DNA damage was slightly lower in cells isolated from
mice treated with AA-Cur suggesting protective activity
of AA-Cur.
Numerous studies have demonstrated anti-inﬂammatory
activity of curcumin manifesting in reduced serum levels of
many cytokines such as TNF, IFN-γ, IL-1α, IL-1β, MCP-1,
IL-6.39 The majority of this type of research has been carried
out using experimental animal models of inﬂammatory dis-
eases, for example, arthritis, inﬂammatory bowel disease,
multiple sclerosis, colitis or psoriasis.40–44 To exclude any
detrimental effect of AA-Cur on the immune system we
compared the basal levels of chosen cytokines in sera of
control- vs AA-Cur-treated mice. The strongest decrease in
cytokine levels in response to AA-Cur was observed for IL-23
and IL-1α. IL-23 is the cytokine essential for inducing differ-
entiation of CD4+ Tcells into T helper cells that secrete IL-17
(Th17), which is a key proinﬂammatory cytokine involved,
among others, in the pathogenesis of T-cell-mediated autoim-
mune diseases.45,46 Our results are in agreement with the
studies by Brück et al and Dolati et al, who recently elucidated
the mechanism of anti-inﬂammatory activity of curcumin in
IL-23/Th17-mediated autoimmune diseases. They demon-
strated that suppression of IL-23 expression in response to
curcumin results from activation of STAT3, which negatively
regulates transcription of IL-23.47,48 Our observation that in
Figure 8 Analysis of anti-tumor activity of intravenously administered AA-Cur.
Notes: (A) C57BL/6 mice bearing MC38-CEA subcutaneous tumors and (B) BALB/c mice bearing orthotopic 4T1 breast tumors were injected iv with of 0.9% NaCl or AA-
Cur (70 mg/kg bm). Two days after the last injection animals were sacriﬁced and isolated tumors were weighted. Each point represents individual mouse. The line for each
group represents the mean ± SD (n=9 for MC38-CEA tumors and n=12 for 4T1 tumors).
Abbreviations: AA-Cur, alginate-curcumin conjugate; CEA, carcinoembryonic antigen.
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response to AA-Cur the serum levels of several cytokines are
slightly decreased suggests that curcumin in this complex has
an ability to keep immune system activity at a low basal level.
Our previous in vitro observations demonstrated high
cytotoxicity of AA-Cur against various cancer cell lines
including murine colon adenocarcinoma MC38-CEA and
mammary carcinoma 4T1 cells.16 However, the results of
in vivo studies performed using these two tumor models
are less spectacular. The regimen of four doses of AA-Cur
given at 1-week intervals led to average 44% and 31%
inhibition of MC38CEA and 4T1 tumor growth, respec-
tively. However, big variations in the ﬁnal tumor sizes
within experimental groups caused a lack of statistical
signiﬁcance of the tumor size differences between control-
and AA-Cur-treated animals.
Similar level of curcumin-mediated tumor growth
inhibition was observed by Wang et al, who demon-
strated statistically signiﬁcant ca. 34% reduced size of
Figure 9 Cytokine levels in sera of MC38-CEA tumor-bearing mice treated with AA-Cur.
Notes: C57/BL/6 mice bearing MC38-CEA tumors were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm). Three days after the last injection, mice were euthanized.
Each point represents individual mouse. The line for each group represents the mean ± SD (n=7).
Abbreviations: AA-Cur, alginate-curcumin conjugate; CEA, carcinoembryonic antigen; IFN, interferon; TNF, tumor necrosis factor.
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human breast MDA-MB-231 tumors growing in nude
mice injected iv with micelles of hyaluronian-curcu-
min conjugates as compared to saline-injected animals.
However, in this case, mice obtained much higher total
doses of curcumin (10 doses of 25 mg curcumin per
1 kg of body mass) than in our studies (4 doses of
3.15 mg curcumin per 1 kg of body mass).49 Similarly,
a conjugate of curcumin with albumin (BSA-Cur)
administered intraperitoneally, reduced cancer cells
growth by 30% in Dalton’s lymphoma ascites mouse
model. However, in this case, unlike in solid tumors,
all cancer cells were exposed to curcumin immediately
after the conjugate administration.50
Detailed pharmacokinetic studies may help to design the
optimal therapeutic dosing regimen. It is also possible that
AA-Cur will be more effective against hematologic malignan-
cies than solid tumors. Because curcumin is often considered
as a drug in combined therapy rather than a monotherapeutic
agent, various curcumin formulations might be compatible
with other proposed components of therapy.51,52
Many anti-tumor approaches aim at boosting the anti-
cancer response of the immune system. There is a growing
need for new drugs with potent immunomodulatory activity.
Downregulation of IFN-γ synthesis by curcumin has been
reported by other groups andwas considered as negative effect
of this compound on anti-tumor immune response.53,54 On the
Figure 10 Cytokine levels in sera of 4T1 tumor-bearing mice treated with AA-Cur.
Notes: BALB/c mice bearing orthotopic 4T1 breast tumors were injected iv with 0.9% NaCl or AA-Cur (70 mg/kg bm). Three days after the last injection mice were
euthanized. Each point represents individual mouse. The line for each group represents the mean ± SD (n=7). Due to technical problems analysis of TNF was not possible.
Abbreviations: AA-Cur, alginate-curcumin conjugate; IFN, interferon; TNF, tumor necrosis factor.
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other hand, studies by Bhattacharyya et al demonstrated that
curcumin may prevent Tregs suppressor activity in tumor-
bearing animals by downregulating synthesis of IL-10.55
The results of our study indicate thatAA-Cur does not have
strong immunoregulatory impact on the immune cells of
tumor-bearing mice. Whether these small changes in serum
cytokine levels reﬂect changes in anti-tumor activity of
immune cells in curcumin-treated mice requires further
studies.
Conclusion
We examined toxicity and anticancer activity of alginate-
curcumin conjugate (AA-Cur), which forms colloidally
stable micelles. Our results indicate that AA-Cur adminis-
tered iv four times at one-week intervals in a dose of 3.15
mg curcumin per 1 kg bm does not have any toxic effects
toward blood- and bone marrow cells as well as the liver,
kidney and spleen, and leads to slightly lower serum levels
of certain cytokines. The same dosing regimen of AA-Cur
results in only moderate reduction of size of two types of
tumors. Thus, the design of the best scheme of medical
application of this safe curcumin derivative for the therapy
of cancer or inﬂammatory diseases requires further studies.
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